A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Chronic Hepatitis C

In brief

The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of BMS-650032 in subjects with chronic hepatitis C infection

Key facts

Study ID

NCT00559247

Run by

Bristol-Myers Squibb

People needed

24

Starts

2008-01-01

Expected to finish

2008-07-01

Last updated by the study team

2010-09-13

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Chronically infected with HCV genotype 1
• Treatment naive or treatment non-responders or treatment intolerant
• HCV RNA viral load of ≥10*5 IU/mL
• BMI 18 to 35kg/m²

You may not qualify if…

• Any significant acute or chronic medical illness which is not stable or is not controlled with medication and not consistent with HCV infection
• Major surgery within 4 weeks of study drug administration and any gastrointestinal surgery that could impact the absorption of study drug
• Co-infection with HIV or HBV
• Women of childbearing potential

Where it is running

• West Coast Clinical Trials, Llc — Cypress, California, United States
• Orlando Clinical Research Center — Orlando, Florida, United States
• Parexel International Corporation — Baltimore, Maryland, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Alamo Medical Research — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.